Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective-Reference-Cited by-同舟云学术

Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective

Published:2024-01 Issue: Volume:17 Page:
ISSN:1179-5514
Container-title:Clinical Medicine Insights: Endocrinology and Diabetes
language:en
Short-container-title:Clin Med Insights Endocrinol Diabetes

Author:

Kalra Sanjay¹,Zargar Abdul Hamid²,Sridhar GR³,Das Ashok Kumar⁴,Ahmed Jamal⁵,Mohan Jagdish Chander⁶,Vijayakumar G⁷,Kumar Ajay⁸,Sahay Rakesh Kumar⁹,Ayer Vageesh¹⁰,Pandit Kaushik¹¹,Bantwal Ganapathi¹²,Srinivas Arun¹³,Unnikrishnan AG¹⁴,Jindal Sushil¹⁵,Ray Saumitra¹⁶,Baruah Manash P¹⁷,Ganguly Kajal¹⁸,Mittal Sachin¹⁹,Joshi Ameya²⁰,George Joe²¹,HK Ganesh²²,Kapoor Nitin²³,Ramakrishnan Santosh²⁴,Shah Chetan²⁵,Dhingra Atul²⁶,Sharma Balram²⁷

Affiliation:

1. Bharti Hospital, Karnal, Haryana, India

2. Centre for Diabetes and Endocrine Care, Srinagar, Jammu and Kashmir, India

3. Endocrine and Diabetes Centre, Visakhapatnam, Andhra Pradesh, India

4. Pondicherry Institute of Medical Sciences, Pondicherry, India

5. Diabetes & Endocrinology Super Specialty Center, Aligarh, Uttar Pradesh, India

6. Department of Cardiology, Jaipur Golden Hospital, Delhi, India

7. Diabetes Medicare Centre, Apollo Specialty Hospital, Chennai, Tamil Nadu, India

8. Diabetes Care and Research Centre, Patna, Bihar, India

9. Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India

10. Department of Endocrinology, St. John’s Hospital, Bengaluru, Karnataka, India

11. Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India

12. Department of Endocrinology, St John’s Medical College, Bengaluru, Karnataka, India

13. Department of Cardiology, Apollo Hospital, Mysore, Karnataka, India

14. Chellaram Diabetes Institute, Pune, Maharashtra, India

15. Department of Endocrinology, People’s College of Medical Sciences, Bhopal, Madhya Pradesh, India

16. Vivekananda Institute of Medical Sciences, Kolkata, West Bengal, India

17. Department of Endocrinology, Apollo Excel Hospital, Guwahati, Assam, India

18. Department of Cardiology, N.R.S. Medical College, Kolkata, West Bengal, India

19. Department of Endocrinology, Fortis Hospital, Mohali, Chandigarh, India

20. Department of Endocrinology, Endocrine and Diabetes Clinic, Mumbai, Maharashtra, India

21. Department of Endocrinology, Endodiab Clinic, Calicut, Kerala, India

22. Mangalore Endodiab Clinic; Department of Endocrinology, Diabetes & Metabolism A J Institute of Medical Sciences, Mangalore, Karnataka, India

23. Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India

24. Magna Centre for Obesity, Diabetes and Endocrinology, Hyderabad, Telangana. India

25. Heart Rhythm Clinic, Mumbai, Maharashtra, India

26. Department of Endocrinology, Gangaram Bansal Hospital, Sri Ganganagar, Rajasthan, India

27. Department of Endocrinology, S.M.S. Medical College and Hospital, Jaipur, Rajasthan, India

Abstract

Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.

Funder

USV Private Limited, India

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/11795514231203911

Reference58 articles.

1. The Times of India. Why India is diabetes capital of the world. The Times of India. 2022. Accessed January 15, 2023. https://timesofindia.indiatimes.com/india/why-india-is-diabetes-capital-of-the-world/articleshow/95509990.cms

2. DPP-4 Inhibition and the Path to Clinical Proof

3. Validation of RSSDI therapeutic wheel with clinical experience of Indian physicians